Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 in children with blood and cancer disorders: An experience from India

Keywords: COVID-19, Pediatric hematology oncology, India, Outcomes

To the editor:

Coronavirus disease-2019 (COVID-19) is caused by severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and has been declared as a pandemic due to rapid global spread. Children and young adults usually have milder course of illness & good outcome in comparison to adults who are elderly or have co-morbidities [1,2]. Children with blood and cancer disorders are at high-risk of getting COVID-19 due to frequent visits to the hospital to get chemotherapy or supportive care [1]. Children with cancer are immunosuppressed and even after completion of chemotherapy, the immune dysfunction may persist for several months [3]. Severe infections due to human coronaviruses (HCoV) in immunocompromised children have been reported [4] and a similar impact was expected in children on chemotherapy due to SARS-CoV-2. But so far, we are still learning about impact of COVID-19 in children with blood & cancer disorders [1]. A strong association of cycle threshold (Ct) values of virus by the polymerase chain reaction (PCR) test with the severity of disease, mortality & laboratory parameters has been reported [5]. In one study it was observed that replication of SARS-CoV-2 in older children leads to similar levels of viral nucleic acid as in adults, but significantly greater amounts of viral nucleic acid are detected in children younger than 5 years [6]. In India, although government of India has provided a treatment protocol to manage COVID-19 but for children with COVID-19; no specific treatment has been recommended [7]. Increased morbidity and mortality have been reported in adult cancer patients with COVID-19 and also delivery of cancer care has also been affected [8–14]. We report here our experience of diagnosing and managing COVID-19 in children with blood and cancer disorders in India.

We retrospectively studied outcome of children with blood & cancer disorders diagnosed with COVID-19 between February to October 2020. All were screened with nasopharyngeal swab for SARS-CoV-2 by RT-PCR prior to inpatient admission or if child had symptoms of COVID-19. Ct values were noted. Positive patients were isolated for at least 14 days and retested as per hospital policy. A total of 55 patients were tested for SARS-COV-2 prior to 252 in-patient admissions. COVID-19 was detected in 13 patients. Results are shown in Table 1. COVID-19 was detected in 13 patients (leukemia-3, solid tumors-7, thalassemia major-2 and aplastic anemia-1). All were male and had median age of 8 years. SARS-COV-2 PCR was tested 369 times in these 55 patients; test positivity rate was 8.1% (30/369). Five patients who were tested by labgun kit had median Ct value of 12.74 (7.24–25.38) for N gene and 13.82 (11.38–26.34) for RDRp gene. By TaqPath kit, 5 patients were tested had median Ct values of N gene – 30.90 (19.25–32.52) & for ORF1 gene-30 (29.30–32). One patient tested by FTD kit had Ct value of 22.9. Two patients were tested by different kit so Ct values are not comparable. All except 3 children were managed at home. One child with aplastic anemia needed multiple admissions for transfusions. He died 3-weeks later due to Klebsiella sepsis. One child with Wilms tumor with Mulibrey-Nanism syndrome with atrial flutter needed intensive care but recovered fully 2 days later. Third child with brain stem glioma on ventilator got infected during radiotherapy. He restarted radiotherapy after clearance of the virus. There was mean treatment delay of 21.6 days (14–39 days). Three children had reactivation after administration of further chemotherapy.

In our study, 3 children had asymptomatic reactivation during further chemotherapy and few had PCR positivity for more than 2 weeks. Out of the three children with reactivation we have previously reported 2 children [15]. In one child with neuroblastoma who had reactivation we did whole genome sequencing of the virus in samples taken from both episodes and found that it is reactivation of same virus and not a new infection [16]. As per WHO guidelines, the chances of culturing virus decline to 6% after 10 days from onset of symptoms [17]. Similar results were observed with smaller studies that recognized infectious virus can shed for 8 or 9 days [18] and others signifying correlation between Ct value/viral load and cultivable virus ([18,19]). Previous studies have reported the correlation between Ct value and disease severity ([20–22]). Lower Ct values from respiratory samples were associated with more severe disease & viral load determined via Ct values correlated with disease severity ([23,24]). Our study showed that all immunocompromised patients were mostly asymptomatic irrespective of the Ct values. In contrast to previous studies, we found no significant correlation between Ct values and severity of disease in children with hematopoietical disorders. Ct values were highly variable.

In our study, a patient with case of CNS relapse of ALL treated on BFM REZ protocol and Rituximab had persistent PCR positivity and also had reactivation after next course of chemotherapy. Rituximab
may be the possible cause of prolonged persistence of covid or reactivation of covid. Similar results have been reported in patients treated with Rituximab and getting Covid19 [25-30]. In our study, a child with a severe aplastic anemia developed COVID-19 after a delay in chemotherapy. Post bone marrow transplant, SARS-COV-2 infection similar to HCoV infection can increase the complications, morbidity & mortality [32–34]. In our study, two patients underwent bone marrow transplant (BMT) uneventfully after recovering from COVID-19 (autologous stem cell transplant for neuroblastoma and allogenic BMT for thalassemia). Viral reactivation was not detected. In our study, we found that planned therapy was delayed by 14–39 days with median value 14 days. Similar rescheduling & delay in chemotherapy has been observed in other centres too due to COVID-19 infection [35].

Varied outcomes of Covid19 in children with cancer has been reported from different parts of the world [15,16,35–40]. Similar to our study most studies suggest that diagnosis of active cancer alone cannot be ruled out.

Table 1
Details of children with blood and cancer disorders diagnosed with COVID19.

| SN | Age | Sex | Dx | Delay in Rx (days) | PCR +ve (time) | Start | Laggun kit Ct values | Tagpath Ct values | FTD kit Ct values | Outcome | Symptoms | Rx | Phase of Rx before COVID19 diagnosis |
|----|-----|-----|----|-------------------|---------------|-------|----------------------|------------------|------------------|---------|----------|----|-----------------------------|
| 1  | 14  | M   | ALL | 14                |               | 0     | NA                   | NA               | 32.52            | NA      | Alive    | None | BFM95- IB phase             |
| 1b | 14  | M   | ALL | 21                |               | 2     | 71                   | NA               | 19.25            | 18.02 | Alive    | None | HCG BFM95-HDMTX              |
| 2  | 8   | M   | ALL | 14                |               | 1     | 0                    | NA               | 22.92            | Alive  | None     | None | HD-ARAC                      |
| 3  | 3   | M   | RMS | 14                |               | 1     | 0                    | NA               | 29.33            | 23.37 | Alive    | None | VAC                         |
| 4a | 3   | M   | NB  | 21                |               | 2     | 0                    | NA               | 14.59            | 17.48 | Alive    | None | Post-surgery                |
| 4b | 3   | M   | NB  | 22                |               | 3     | 42                   | 22.37            | 22.35            | NA     | Alive    | None | OJEC                        |
| 5  | 2   | M   | WT  | 14                |               | 1     | 0                    | NA               | 32.48            | 35.45 | Alive    | AF   | SIOP-WT                      |
| 6  | 1   | M   | TM  | 39                |               | 2     | 0                    | NA               | 30.03            | 27.29 | Alive    | None | Hydroxyurea                  |
| 7  | 15  | M   | TM  | 14                |               | 1     | 0                    | NA               | 25.36            | 28.03 | Alive    | None | None                         |
| 8  | 10  | M   | HL  | 14                |               | 1     | 0                    | 24.78            | 26.22            | NA     | Alive    | None | None                         |
| 9a | 6   | M   | ALL | 28                |               | 4     | 0                    | 12.74            | 13.82            | NA     | Alive    | None | R1 block BFMRZ+ R            |
| 9b | 6   | M   | ALL | 22                |               | 3     | 39                   | 18.92            | 18.85            | NA     | Alive    | None | R2 block BFMRZ+ R            |
| 10 | 10  | M   | SAA | 29                |               | 4     | 0                    | 7.24             | 11.38            | NA     | Died     | None | ATG & CSA                    |
| 11 | 15  | M   | AM  | 14                |               | 1     | 0                    | NA               | 30.38            | 28.04 | Alive    | None | None                         |
| 12 | 15  | M   | NB  | 30                |               | 2     | 0                    | 13.3             | 13.6             | NA     | Alive    | Mild  | No Radiotherapy              |
| 13 | 12  | M   | ES  | 14                |               | 1     | NA                   | NA               | *                | *     | Alive    | None | Cycle 4 VDCIJE                |

SN- Serial Number, Yr.- year, Dx- Diagnosis, Rx-Treatment, PCR- Polymerase chain reaction, +ve-positive, Ct-cycle threshold, M-Male, ALL- Acute lymphoblastic leukemia, NB- Neuroblastoma, RMS-Rhabdomyosarcoma, WT-Wilms Tumor, TM-Thalassemia major, HL- Hodgkin Lymphoma, CR-Complete Remission, SAA- Severe Aplastic Anemia, AM- Atypical Meningioma, BSG- Brain stem glioma, ES-Ewing Sarcoma, NA- Not applicable, *- Ct values not available.

Disclosure
All authors have nothing to declare.

Conflict of Interest
Nothing to declare
patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2020;5:1558–61. https://doi.org/10.1016/j.hbst.2020.07.005.

[12] Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CC19): a cohort study. Jun 20 Lancet 2020;395(10241):1907–18. https://doi.org/10.1016/S0140-6736(20)31177-5. Epub 2020 May 28.

[13] Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma: a case series. IDCases 2021;23:e01018. https://doi.org/10.1016/j.icases.2021.04.008. Epub 2021 Apr 15.

[14] Shi F, Wu T, Zhu X, Ge Y, Zeng X, Chi Y, et al. COVID-19 reinfection in two children with cancer. Pediatr Hematol Oncol 2021. https://doi.org/10.1080/08880018.2021.1985276.

[15] Yadav SP, Wadhwa T, Thakkar D, Kapoor R, Rastogi N, Sarma S. COVID-19 reinfec- tion in two children with cancer. Pediatr Hematol Oncol 2021. https://doi.org/10.1080/08880018.2021.1985276.

[16] Yadav SP, Thakkar D, Bhoyar RC, Jain A, Wadhwa T, Imam M, et al. Asymptom- atic reactivation of SARS-CoV-2 in a child with neuroblastoma characterized by whole genome sequencing. IDCases 2021;23:e01018. https://doi.org/10.1016/j.icases.2021.04.008. Epub 2021 Apr 15.

[17] World Health Organization. Clinical management of COVID-19: interim guid- ance. 27 May 2020. World Health Organization; 2020. https://www.who.int/docs/default-source/coronaviruse/technical-guidance/clinical-management-of-covid-19-eng.pdf?sfvrsn=1.

[18] Perera RAPM, Tso E, Tsang OTY, Tsang DNC, Fung K, Leung YWY, et al. SARS-CoV-2 infection in two children with cancer: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021;6(1):49–51. https://doi.org/10.1016/j.hbst.2020.07.005.

[19] Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, severe cases of COVID-19. Jun Lancet Infect Dis 2020;20(6):656–61. https://doi.org/10.1016/S1470-214X(20)30182-X. Epub 2020 May 12.

[20] Amir M, Chang C, Chang H, Chen W, Chuang F, Chiu W, et al. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience. Jul Br J Haematol 2020;190(2):e67–70. https://doi.org/10.1111/bjh.16856. Epub 2020 Jun 23.

[21] Saah R, Obeid A, Gachi F, Boudiaf H, Sargysan L, Al-Saad K, et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on pediatric oncology care in the Middle East, North Africa, and West Asia region: a report from the Pediatric Oncology East and Mediterranean (POEM) group. Sep. 15 Cancer 2020;126(18):4235–45. https://doi.org/10.1016/j.caner.2020.07.018. Epub 2020 Jul 10.

[22] de Rojas P, Pérez-Martínez A, Cela E, Baragán M, Galán V, Mata C, et al. COVID-19 infection in children and adolescents with cancer in Madrid. Jul Pediatr Blood Cancer 2020;67(7):e28397. https://doi.org/10.1002/pbc.28397. Epub 2020 May 8.

[23] Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C, et al. Flush survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Jun Eur J Cancer 2020;132:11–6. https://doi.org/10.1016/j.ejca.2020.03.021. Epub 2020 Apr 7.

[24] Andrè N, Rouger-Gaudichon J, Brethon B, Philippin A, Thébault E, Pertussel S, et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: high risk of severe forms?. Jul Pediatr Blood Cancer 2020;71(12):1323–9. https://doi.org/10.1016/j.pbc.2020.08.017. Epub 2020 Aug 22.

[25] Boulad F, Kamboj M, Bouvier N, Mauguen A, Kung AL. COVID-19 in children with cancer in new york city. Sep. 1 JAMA Oncol 2020;6(9):1459–60. https://doi.org/10.1001/jamaoncol.2020.2028.

[26] Ferrari A, Zecca M, Rizzari C, Porta F, Provenzi M, Marimoni M, et al. Children with cancer in the time of COVID-19: an 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy. Aug Pediatr Blood Cancer 2020;67(8):e28410. https://doi.org/10.1002/pbc.28410. Epub 2020 May 26.

Anjali Yadav
Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India

Dhwaneet Thakkar
Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India

Teena Wadhwa
Department of Microbiology, Medanta The Medicity, Gurgaon, Haryana, India

Smita Sarma
Department of Microbiology, Medanta The Medicity, Gurgaon, Haryana, India

K. Upasana
Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India

Neha Rastogi
Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India

Satyaa Prakash Yadav* 
Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana, India

* Corresponding author. Pediatric Hematology Oncology & BMT Unit, Cancer Institute, Medanta - The Medicity, Gurgaon, 122001, India.

E-mail address: satyaa_1026@hotmail.com (S.P. Yadav).

8 April 2021 Available online 15 October 2021

63